TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · IEX Real-Time Price · USD
5.55
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
5.43
-0.12 (-2.16%)
Pre-market: Jul 20, 2024, 9:28 AM EDT

TriSalus Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020
Revenue
21.9818.5112.48.40
Revenue Growth (YoY)
68.96%49.31%47.58%--
Cost of Revenue
2.912.612.261.190
Gross Profit
19.0715.9110.147.210
Selling, General & Admin
45.0640.5525.2217.020.11
Research & Development
29.7329.5121.3614.220
Other Operating Expenses
0.360.380.42-0.750
Operating Expenses
75.1470.444730.490.11
Operating Income
-56.08-54.53-36.86-23.29-0.11
Interest Expense / Income
0.010.0201.760
Other Expense / Income
7.884.4810.323.80.6
Pretax Income
-63.97-59.03-47.18-28.84-0.71
Income Tax
0.020.010.0100
Net Income
-63.99-59.04-47.19-28.85-0.71
Shares Outstanding (Basic)
239008
Shares Outstanding (Diluted)
239008
Shares Change
44.27%2934.71%41.31%-97.37%-
EPS (Basic)
-2.67-6.73-161.55-131.65-0.09
EPS (Diluted)
-2.67-6.73-161.55-131.65-0.09
Free Cash Flow
-51.52-51.17-33.1-23.96-0.68
Free Cash Flow Per Share
-2.21-5.45-106.91-109.33-0.08
Gross Margin
86.74%85.93%81.79%85.80%-
Operating Margin
-255.08%-294.58%-297.30%-277.18%-
Profit Margin
-291.08%-318.93%-380.60%-343.35%-
Free Cash Flow Margin
-234.34%-276.41%-266.97%-285.14%-
EBITDA
-63.18-58.31-46.78-26.62-0.71
EBITDA Margin
-287.38%-315.01%-377.31%-316.83%-
Depreciation & Amortization
0.780.70.40.460
EBIT
-63.96-59.01-47.18-27.08-0.71
EBIT Margin
-290.94%-318.80%-380.52%-322.35%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).